We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Emerging Trends in Immunotherapy for Cancer.
- Authors
Mishra, Alok K.; Ali, Amjad; Dutta, Shubham; Banday, Shahid; Malonia, Sunil K.
- Abstract
Recent advances in cancer immunology have enabled the discovery of promising immunotherapies for various malignancies that have shifted the cancer treatment paradigm. The innovative research and clinical advancements of immunotherapy approaches have prolonged the survival of patients with relapsed or refractory metastatic cancers. Since the U.S. FDA approved the first immune checkpoint inhibitor in 2011, the field of cancer immunotherapy has grown exponentially. Multiple therapeutic approaches or agents to manipulate different aspects of the immune system are currently in development. These include cancer vaccines, adoptive cell therapies (such as CAR-T or NK cell therapy), monoclonal antibodies, cytokine therapies, oncolytic viruses, and inhibitors targeting immune checkpoints that have demonstrated promising clinical efficacy. Multiple immunotherapeutic approaches have been approved for specific cancer treatments, while others are currently in preclinical and clinical trial stages. Given the success of immunotherapy, there has been a tremendous thrust to improve the clinical efficacy of various agents and strategies implemented so far. Here, we present a comprehensive overview of the development and clinical implementation of various immunotherapy approaches currently being used to treat cancer. We also highlight the latest developments, emerging trends, limitations, and future promises of cancer immunotherapy.
- Subjects
UNITED States. Food &; Drug Administration; MONOCLONAL antibodies; IMMUNE checkpoint inhibitors; KILLER cells; THERAPEUTICS; IMMUNE system; IMMUNOTHERAPY; ANTIBODY-dependent cell cytotoxicity
- Publication
Diseases, 2022, Vol 10, Issue 3, pN.PAG
- ISSN
2079-9721
- Publication type
Article
- DOI
10.3390/diseases10030060